QCG
AGRX

Quadrant Capital Group’s Agile Therapeutics AGRX Stock Holding History

Quadrant Capital Group’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Hold
0
– – – 2706
2021
Q2 		– Hold
0
– – – 2624
2018
Q3 		– Sell
-1
Closed -$1K – 2208
2018
Q2 		$1K Hold
1
– – ﹤0.01% 2087
2018
Q1 		$6K Hold
1
– – ﹤0.01% 1500
2017
Q4 		$7K Hold
1
– – ﹤0.01% 1375
2017
Q3 		$11K Hold
1
– – ﹤0.01% 1154
2017
Q2 		$9K Hold
1
– – ﹤0.01% 1156
2017
Q1 		$8K Buy
+1
New +$5.03K ﹤0.01% 1184

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quadrant Capital Group's AGRX Position: Q3 2021 in Review

Quadrant Capital Group held its Agile Therapeutics (AGRX) position steady in Q3 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2706.

Quadrant Capital Group first reported a position in AGRX in Q1 2017 and has held it in 6 quarters since. The position peaked at $11K in Q3 2017. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

  • Quadrant Capital Group held 0 shares of Agile Therapeutics worth $0 as of Q3 2021.
  • Quadrant Capital Group left its Agile Therapeutics share count unchanged in Q3 2021.
  • Agile Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q3 2021, its #2706 holding.
  • Quadrant Capital Group first reported a position in Agile Therapeutics in Q1 2017 and has held it in 6 quarters since.
  • Quadrant Capital Group's Agile Therapeutics position peaked at $11K in Q3 2017.
  • 49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on Quadrant Capital Group's 13F filing for Q3 2021, filed 12 Nov 2021.